“This approval is a significant win for patients, offering a first-line biologic option when topical therapies are insufficient,” said Jonathan Silverberg, Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC and a key investi...
The recent TGA approval of dupilumab, a biologic therapy aimed at targeting specific immune markers, provides new hope in the treatment of adults with moderate-to-severe atopic dermatitis. Atopic dermatitis (AD) can be burdensome to the individual and the healthcare system. Although 30% of the...
[6]Zouboulis C C, Passeron T, Pariser D, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III tri...
"We are delighted to introduce Ebglyss as a new biologic treatment for Korean people with moderate to severe atopic dermatitis, addressing the high unmet medical need,” Elli Lilly Korea Immunology Business Unit Director Kim Tae-hyun said. “Following the approvals of IL-17A inhibitor Talz, JAK...
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD Dupixent approval historyRetevmo (selpercatinib) Capsules and Tablets Labeling Revision Approved: September 27, 2024 Date of Original Approval: May 8, 2020 Retevmo (selpercatinib) is a kinase inhibitor used ...
Dupixent, a novel biologic agent, is used to treat atopic dermatitis. More recently ADBRY (tralokinumab-ldrm) has been approved; this drug targets IL-13. Other Immunosupressants If all else fails, systemic therapy with cyclosporine or azathioprine may help. ...
Multiple biologic processes such as cell proliferation, differentiation, function activation/inhibition, and survival/apoptosis are mediated by cell signalization driven by JAK/STAT family [13]. It is especially important for the signalization of a range of cytokines and growth factors. Nevertheless, ...
administered twice daily for 12 weeks, enhances parameters such as the lymph node size and the percentage of naïve B cells in peripheral blood over placebo (Rao et al.2023). AE include headache, sinusitis, and atopic dermatitis. Leniolisib received orphan drug designation, rare pediatric dise...
for the treatment of mild to moderate AD in more than 15 years. It is approved for patients 2 years of age or older. Dupilumab, the second new medication, is a biologic therapy given by injection forpatients18 years or older with moderate to severe AD who haven't responded to, or can...
Editor's note: The numbers for our annual roundup typically vary slightly from theFDA's official list,because our report includes approvals for biologic therapeutics and vaccines but excludes diagnostic imaging agents, which are represented on the FDA's list. ...